Herman Joan M sold $801K of PAYS

Herman Joan M (EVP, Operations) sold 100,000 shares of Paysign, Inc. (PAYS) at $8.01 ($0.80M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Herman Joan M
Published Jun 30, 2026, 11:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PAYS
Neutral
medium confidence
Mentioned
$PAYS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PAYSNeutralLow
01

Why it matters

The newest fact is the specific insider sale size, price, and post-transaction holdings, which can marginally affect sentiment but usually not fundamentals when tied to a 10b5-1 plan.

02

Market read

Traders may note the insider’s scheduled selling activity and the execution price, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not disclose reasons for the sale beyond the plan; without concurrent news (earnings, guidance, contracts), the signal is mostly informational rather than directional.

Relevance 4/10Novelty 5/10Timing: new Form 4 filed 2026-06-30 (sale dated 2026-06-26)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Paysign, Inc.

Company-level read

Ticker impact

$PAYSNeutralMedium confidence
Context

SEC Form 4 shows EVP Herman Joan M sold 100,000 shares of Paysign at $8.0114 on 2026-06-26 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only unless paired with other disclosures.

Evidence & confidence

The filing is a primary-source Form 4 and is company-specific, but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive value.

Market effects

No clear sector read-through; this is an individual insider transaction rather than an industry catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations; traders may ignore it unless follow-on sales cluster.

Key entities

  • Paysign, Inc.

    Subject of the Form 4 insider sale by EVP Herman Joan M.

  • Herman Joan M

    EVP, Operations; sold 100,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PAYSMedAI 8/10

Paysign (PAYS) Q3 2026 Earnings Call Transcript

Paysign (PAYS) reported Q3 2026 earnings, highlighting growth in its patient affordability business with revenue doubling to $16.6M YoY. Plasma revenue rose 7.5% to $13.8M. The company expects to offset a loss of 113 plasma centers with new clients. Patient affordability drove strong margins and operating leverage, while Apherion, a plasma industry software, is under regulatory review.

$PAYSHigh

Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8% Patient Affordability Growth Drives Revenue and Margin Expansion Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adju

$PAYSHigh

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Oper